Drugs / BL0020
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07550842 | Jun 2026 → Apr 2028 expected | small cell lung carcinoma | Shanghai Best-Link Bioscience, LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05886868 | Oct 2023 → Jul 2024 | neoplasm | Shanghai Best-Link Bioscience, LLC | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07414927 | Mar 2026 → Dec 2027 expected | small cell lung carcinoma | Shanghai Best-Link Bioscience, LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL0020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05886868 ↗ |
| Modality | Other / unclassified | “BL0020 is a polymer-drug conjugate” NCT07414927 ↗ |
| Route | Intravenous | “BL0020 will be administered via intravenous infusion” NCT05886868 ↗ |